Best Stocks Under $2 Right Now → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Clearside BiomedicalNASDAQ:CLSDStock Price: $1.54 (-$0.13)P/E Ratio: -2.91Market Cap: $115.08 millionAverage Trading Volume: 351,720 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (208.4% Upside)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Aptose BiosciencesNASDAQ:APTOStock Price: $1.65 (+$0.15)P/E Ratio: -0.21Market Cap: $25.91 millionAverage Trading Volume: 91,797 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.80 (1,101.1% Upside)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.#3 - Integra ResourcesNYSEAMERICAN:ITRGStock Price: $0.73 (+$0.03)P/E Ratio: -1.15Market Cap: $64.84 millionAverage Trading Volume: 103,113 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.75 (411.6% Upside)Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.#4 - Ur-EnergyNYSEAMERICAN:URGStock Price: $1.60 (+$0.02)P/E Ratio: -13.29Market Cap: $449.20 millionAverage Trading Volume: 3.21 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.76 (73.2% Upside)Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. The company was incorporated in 2004 and is headquartered in Littleton, Colorado.#5 - Unicycive TherapeuticsNASDAQ:UNCYStock Price: $1.41 (-$0.05)P/E Ratio: -0.81Market Cap: $49.00 millionAverage Trading Volume: 337,367 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.30 (488.7% Upside)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.#6 - RallybioNASDAQ:RLYBStock Price: $1.83 (+$0.24)P/E Ratio: -0.99Market Cap: $69.19 millionAverage Trading Volume: 225,922 sharesConsensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.60 (588.5% Upside)Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. The company was founded in 2018 and is headquartered in New Haven, Connecticut.AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.#7 - Milestone PharmaceuticalsNASDAQ:MISTStock Price: $1.80P/E Ratio: -1.29Market Cap: $60.26 millionAverage Trading Volume: 357,724 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.20 (522.2% Upside)Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.#8 - Gossamer BioNASDAQ:GOSSStock Price: $1.20 (+$0.03)P/E Ratio: -0.86Market Cap: $270.70 millionAverage Trading Volume: 1.10 million sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.05 (570.8% Upside)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.#9 - DZSNASDAQ:DZSIStock Price: $1.31 (+$0.02)P/E Ratio: -0.74Market Cap: $40.82 millionAverage Trading Volume: 185,630 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.67 (408.9% Upside)DZS Inc. provides access and optical networking infrastructure and cloud software solutions in the Americas, Europe, the Middle East, Africa, and Asia. The company offers access edge solutions through DZS Velocity, including voice, high-definition and ultra-high-definition video, highspeed internet access, and business class services; switching and routing products; and XCelerate for increasing the velocity with which service providers can leap to multi-gigabit services. It also provides subscriber edge solutions through DZS Helix comprising optical network terminals (ONTs) and smart gateway solutions for fiber to the x (FTTx) deployment; and connected premises products, consisting of indoor/outdoor ONTs and gateways. In addition, the company offers optical edge solutions through DZS Chronos and DZS Saber, which provides solutions for mobile operators and service providers that enables them to upgrade their mobile fronthaul/midhaul/backhaul systems and migrate to fifth generation wireless technologies. Further, it provides cloud software solutions through DZS Cloud that offers a commercial, carrier-grade network-slicing enabled orchestration platform, which supports open RAN and 4G/5G networks. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc. in August 2020. DZS Inc. was founded in 1996 and is headquartered in Plano, Texas.#10 - Cara TherapeuticsNASDAQ:CARAStock Price: $0.89 (+$0.02)P/E Ratio: -0.41Market Cap: $48.60 millionAverage Trading Volume: 733,392 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.75 (996.6% Upside)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.#11 - Eos Energy EnterprisesNASDAQ:EOSEStock Price: $1.03 (-$0.00)P/E Ratio: -0.48Market Cap: $208.71 millionAverage Trading Volume: 5.32 million sharesConsensus Rating: Moderate Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.08 (490.7% Upside)Eos Energy Enterprises, Inc. designs, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial and industrial (C&I) applications in the United States. The company offers Znyth technology battery energy storage system (BESS), which provides the operating flexibility to manage increased grid complexity and price volatility. Its flagship product is Gen 2.3 battery module. In addition, the company offers Z3 battery module that provides utilities, independent power producers, renewables developers, and C&I customers with an alternative to lithium-ion and lead-acid monopolar batteries for critical 3- to 12-hour discharge duration applications; battery management system, which provides a remote asset monitoring capability and service to track the performance and health of BESS and identify future system performance issues through predictive analytics; and project management and commissioning services, as well as long-term maintenance plans. Eos Energy Enterprises, Inc. is headquartered in Edison, New Jersey.AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.#12 - Purple InnovationNASDAQ:PRPLStock Price: $1.78 (+$0.22)P/E Ratio: -1.60Market Cap: $190.30 millionAverage Trading Volume: 934,534 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.95 (122.5% Upside)Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.#13 - Gold RoyaltyNYSEAMERICAN:GROYStock Price: $1.89 (-$0.10)P/E Ratio: -27.00Market Cap: $275.41 millionAverage Trading Volume: 606,760 sharesDividend Yield: 1.04%<Consensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.28 (73.7% Upside)Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. It focuses on acquiring royalties, streams, and similar interests at varying stages of the mine life cycle to build a portfolio offering near, medium, and longer-term attractive returns for its investors. The company's portfolio consists of net smelter return royalties ranging from 0.5% to 2.0% on 17 gold properties. Gold Royalty Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.#14 - FiscalNoteNYSE:NOTEStock Price: $1.34 (+$0.02)P/E Ratio: -1.54Market Cap: $175.55 millionAverage Trading Volume: 968,267 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.44 (231.2% Upside)FiscalNote Holdings, Inc. operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. The company also delivers that intelligence through its suite of public policy and issues management products, as well as powerful tools to manage workflows, advocacy campaigns, and constituent relationships. It serves a customer base that includes businesses comprising the Fortune 100 companies, government agencies, law firms, professional services organizations, trade groups, and non-profits. FiscalNote Holdings, Inc. is headquartered in Washington, District Of Columbia.#15 - Tigo EnergyNASDAQ:TYGOStock Price: $1.07 (+$0.01)Market Cap: $63.87 millionAverage Trading Volume: 93,050 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.05 (558.9% Upside)Tigo Energy, Inc. provides solar and energy storage solutions for the solar industry. It offers module level power electronics (MLPEs) to maximize the energy output of individual solar modules. The company also provides GO Energy Storage Systems that provide solar energy storage management capabilities; and Energy Intelligence (EI) platform, which provides monitoring and energy demand forecasting capabilities. In addition, it offers GO Battery that provides energy resilience in the event of a grid outage and optimizes energy consumption based on rate plans for home energy needs; GO Inverter, which offers energy conversion for home consumption or export to the grid; GO Link/Automatic Transfer Switch (ATS), a component for battery backup of on-grid systems; and GO Electric Vehicle (EV) Charger to reduce transportation costs. The company serves residential, commercial, and utility sectors through distributors and solar installers in North and South America, Europe, the Middle East, Africa, and the Asia-Pacific regions. Tigo Energy, Inc. was founded in 2007 and is headquartered in Campbell, California.#16 - Energy VaultNYSE:NRGVStock Price: $1.78 (+$0.05)P/E Ratio: -2.62Market Cap: $261.80 millionAverage Trading Volume: 818,306 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $4.38 (145.8% Upside)Energy Vault Holdings, Inc. develops and sells energy storage solutions. The company offers battery energy storage systems for shorter-duration energy storage needs; gravity energy storage systems, including EVx solution; green hydrogen energy storage systems; hybrid energy storage systems; and energy management software platform that orchestrates the management of one or more diverse storage mediums. Its solutions allow utilities, independent power producers, and large energy users to manage their power portfolios and efficiently dispatch power. Energy Vault Holdings, Inc. is based in Westlake Village, California.AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.#17 - Coppernico MetalsOTCMKTS:CPPMFStock Price: $0.02P/E Ratio: 0.22Market Cap: $4.29 millionAverage Trading Volume: 31,700 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.25 (21,150.0% Upside)Copper Mountain Mining Corporation engages in the mining, exploration, and development of mineral properties in Canada. It explores for copper, gold, and silver deposits. The company holds 75% interests in the Copper Mountain mine comprising 135 crown-granted mineral claims, 145 located mineral claims, 14 mining leases, 12 fee simple properties, and seven cell claims that covers an area of approximately 6,354 hectares located to the south of Princeton, British Columbia. Copper Mountain Mining Corporation was incorporated in 2006 and is headquartered in Vancouver, Canada. As of June 20, 2023, Copper Mountain Mining Corporation operates as a subsidiary of Hudbay Minerals Inc.#18 - Karyopharm TherapeuticsNASDAQ:KPTIStock Price: $1.54 (+$0.06)P/E Ratio: -1.23Market Cap: $176.63 millionAverage Trading Volume: 1.77 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.67 (269.2% Upside)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.#19 - Chicken Soup for the Soul EntertainmentNASDAQ:CSSEStock Price: $0.16 (-$0.00)P/E Ratio: -0.01Market Cap: $5.00 millionAverage Trading Volume: 197,903 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.60 (2,863.9% Upside)Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Popcornflix Comedy, Españolflix, and FrightPix. The company distributes and exhibits content through the Crackle Plus and Redbox streaming services including AVOD, FAST, TVOD platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated platforms. It also produces and licenses movies, television series, and programs; and produces long and short-form video content. Chicken Soup for the Soul Entertainment, Inc. was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.#20 - fuboTVNYSE:FUBOStock Price: $1.57 (+$0.01)P/E Ratio: -1.46Market Cap: $468.72 millionAverage Trading Volume: 11.57 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.42 (118.3% Upside)fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. The company's platform allows customers to access content through streaming devices, as well as on SmartTVs, mobile phones, tablets, and computers. fuboTV Inc. was incorporated in 2009 and is headquartered in New York, New York.#21 - Oatly GroupNASDAQ:OTLYStock Price: $1.14 (+$0.05)P/E Ratio: -1.34Market Cap: $673.28 millionAverage Trading Volume: 1.98 million sharesConsensus Rating: Hold (5 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $2.11 (86.3% Upside)Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Sweden. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. The company was founded in 1994 and is headquartered in Malmö, Sweden.#22 - FTC SolarNASDAQ:FTCIStock Price: $0.52 (-$0.07)P/E Ratio: -1.21Market Cap: $65.17 millionAverage Trading Volume: 763,340 sharesConsensus Rating: Hold (2 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.49 (186.1% Upside)FTC Solar, Inc. engages in the provision of solar tracker systems, software, and engineering services in the United States, Asia, Europe, the Middle East, North Africa, South Africa, and Australia. The company offers a self-powered, two-panel in-portrait, and single-axis tracker solution under the Voyager brand name; and a one module-in-portrait solar tracker solution under the Pioneer brand name. Its customers include project developers and solar asset owners, as well as engineering, procurement, and construction contractors that design and build solar energy projects. The company was incorporated in 2017 and is headquartered in Austin, Texas.#23 - Li-CycleNYSE:LICYStock Price: $1.03 (+$0.12)P/E Ratio: -1.34Market Cap: $184.44 millionAverage Trading Volume: 8.47 million sharesConsensus Rating: Hold (3 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.60 (637.8% Upside)Li-Cycle Holdings Corp. engages in the lithium-ion battery resource recovery and lithium-ion battery recycling business in North America. The company offers a mix of cathode and anode battery materials, including lithium, nickel, and cobalt, as well as graphite, copper, and aluminum; and copper and aluminum metals. It also provides hub products, such as lithium carbonate, cobalt sulphate, nickel sulphate, and manganese carbonate. Li-Cycle Holdings Corp. is headquartered in Toronto, Canada.#24 - WW InternationalNASDAQ:WWStock Price: $1.84 (+$0.02)P/E Ratio: -1.15Market Cap: $145.73 millionAverage Trading Volume: 6.60 million sharesConsensus Rating: Hold (4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $9.14 (396.9% Upside)WW International, Inc. provides weight management products and services worldwide. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program through its app and web-based platform; and allows members to inspire and support each other by sharing their experiences with other people on weight health journeys. In addition, it licenses its trademarks and other intellectual property in food, beverages, and other relevant consumer products and services, as well as provides publishing services. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1961 and is headquartered in New York, New York.#25 - DeliverooOTCMKTS:DROOFStock Price: $1.51Average Trading Volume: 1,922 sharesConsensus Rating: Hold (4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/ADeliveroo plc operates an online food delivery platform. It connects local consumers, riders and restaurants, and grocery partners. The company operates in the United Kingdom, Ireland, France, Italy, Belgium, Hong Kong, Singapore, the United Arab Emirates, Kuwait, and Qatar. Deliveroo plc was founded in 2013 and is based in London, the United Kingdom. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: GameStop Stock Downtrend Is Intact: The End Game Draws Near Trump Media & Technology Group Soars on Market Debut 3 Stocks Insiders Are Buying That Analysts Love Should You Buy Boeing Stock After CEO Resignation Announcement? These Are The Most Upgraded Stocks From Q1 4 Overbought Household Names, Time for a Pullback? Top 3 Stocks Bought By Members of Congress In the First Quarter UiPath Cuts Q1 and Raises Full Year Guidance Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.